EMT is the dominant program in human colon cancer.
BACKGROUND
Colon cancer has been classically described by clinicopathologic features that permit the prediction of outcome only after surgical resection and staging.


METHODS
We performed an unsupervised analysis of microarray data from 326 colon cancers to identify the first principal component (PC1) of the most variable set of genes. PC1 deciphered two primary, intrinsic molecular subtypes of colon cancer that predicted disease progression and recurrence.


RESULTS
Here we report that the most dominant pattern of intrinsic gene expression in colon cancer (PC1) was tightly correlated (Pearson R = 0.92, P < 10(-135)) with the EMT signature-- both in gene identity and directionality. In a global micro-RNA screen, we further identified the most anti-correlated microRNA with PC1 as MiR200, known to regulate EMT.


CONCLUSIONS
These data demonstrate that the biology underpinning the native, molecular classification of human colon cancer--previously thought to be highly heterogeneous-- was clarified through the lens of comprehensive transcriptome analysis.
Merck, Sharp and Dohme, West Point, PA 19486, USA.
Andre
A
Loboda
Michael V
MV
Nebozhyn
James W
JW
Watters
Carolyne A
CA
Buser
Peter Martin
PM
Shaw
Pearl S
PS
Huang
Laura
L
Van't Veer
Rob A E M
RA
Tollenaar
David B
DB
Jackson
Deepak
D
Agrawal
Hongyue
H
Dai
Timothy J
TJ
Yeatman
D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000378:metabolism* / Q000473:pathology; D018450:Disease Progression; D058750:Epithelial-Mesenchymal Transition; D020869:Gene Expression Profiling / Q000379:methods; D006801:Humans; D025341:Principal Component Analysis; D012008:Recurrence; D014746:Vimentin / Q000378:metabolism
D014746:Vimentin
J Clin Oncol. 2005 May 20;23(15):3526-35
15908663
Clin Cancer Res. 2007 Jun 15;13(12):3545-51
17575217
Cancer Res. 2006 May 1;66(9):4636-44
16651414
J Natl Cancer Inst. 2002 Apr 3;94(7):513-21
11929952
Clin Cancer Res. 2007 Jun 1;13(11):3207-14
17545524
Genes Dev. 2008 Apr 1;22(7):894-907
18381893
Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):444-53
19190164
Clin Cancer Res. 2009 Dec 15;15(24):7642-7651
19996206
Nat Genet. 2003 Jun;34(2):226-30
12754511
Tumori. 2009 Nov-Dec;95(6):655-64
20210225
Gastroenterology. 2010 Apr;138(4):1406-17
20026115
J Clin Oncol. 2004 May 1;22(9):1564-71
15051756
Gastroenterology. 2010 Mar;138(3):958-68
19914252
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):498-507
17255271
Rev Esp Enferm Dig. 1998 Aug;90(8):563-72
9780789
Cancer Cell. 2009 Jun 2;15(6):489-500
19477428
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):819-26
16467094
Br J Cancer. 2005 Jun 20;92(12):2240-8
15956967
Clin Cancer Res. 2008 Aug 15;14(16):5158-65
18698033
Nature. 2006 Jan 19;439(7074):353-7
16273092
Cancer. 2010 Feb 1;116(3):544-73
19998273
Clin Exp Metastasis. 2008;25(6):657-63
18350253
Genes Chromosomes Cancer. 2009 Nov;48(11):953-62
19672874
Cancer Res. 2005 Mar 15;65(6):2170-8
15781628
Oncogene. 2008 Sep 11;27(40):5359-72
18490921
Nat Cell Biol. 2009 Nov;11(11):1297-304
19801974
BMC Genomics. 2010 Jan 04;11:5
20047688
Clin Exp Metastasis. 2010;27(1):1-9
19882219
BMC Med Genomics. 2010 Jun 30;3:26
20591134
Cell. 2000 Jan 7;100(1):57-70
10647931
Nat Cell Biol. 2008 May;10(5):593-601
18376396